Drug General Information
Drug ID	D0T8MA
Former ID	DIB005567
Drug Name	ATN-224
Synonyms	Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 2	[521926]
Company	University of Michigan
Structure		Download 2D MOL 3D MOL
Formula	C10H30MoN2O2S4
Canonical SMILES	S=[Mo-2](=S)(=S)=S.C[N+](C)(CCO)C.C[N+](C)(CCO)C
CAS Number	CAS 649749-10-0
PubChem Compound ID	18442052
Target and Pathway
Target(s)	Superoxide dismutase [Cu-Zn]	Target Info	Inhibitor	[528378]
BioCyc Pathway	Reactive oxygen species degradation
KEGG Pathway	Peroxisome
	Amyotrophic lateral sclerosis (ALS)
	Huntington's disease
	Prion diseases
NetPath Pathway	TCR Signaling Pathway
Pathway Interaction Database	Validated nuclear estrogen receptor alpha network
	FOXA1 transcription factor network
PathWhiz Pathway	Degradation of Superoxides
Reactome	Platelet degranulation
	Detoxification of Reactive Oxygen Species
WikiPathways	Oxidative Stress
	Copper homeostasis
	Detoxification of Reactive Oxygen Species
	Nifedipine Activity
	Amyotrophic lateral sclerosis (ALS)
	Dopamine metabolism
	AGE/RAGE pathway
	Folate Metabolism
	Vitamin B12 Metabolism
	Selenium Micronutrient Network
References
Ref 521926	ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 528378	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.